How Is The Severe Acute Respiratory-Syndrome Treatment Market Expected To Grow At 15.8% CAGR Over 2025–2029?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Much Will The Severe Acute Respiratory-Syndrome Treatment Market Be Worth By 2029?
In recent times, there has been a swift expansion in the size of the severe acute respiratory-syndrome treatment market. Projections indicate an increase from $3.45 billion in 2024 to $3.94 billion in 2025, with a compound annual growth rate (CAGR) of 14.1%. Key factors driving this growth in the historical period include the worldwide response to pandemic outbreaks, the process of antiviral drug creation, vaccine development, and preparations in public health.
The market size for treatment of severe acute respiratory syndrome is predicted to experience significant growth in the upcoming years. It is estimated to reach a worth of $7.08 billion by 2029, growing at a CAGR of 15.8%. Various factors contributing to this projected growth during the forecast period include advancements in vaccines, the emergence of more broad-spectrum antivirals, and better preparation for pandemics. RNA-targeted therapies, the use of artificial intelligence in drug discovery, global collaborations, and public health education represent the chief trends expected in the predicted growth period.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13027&type=smp
What External And Internal Drivers Are Influencing The Severe Acute Respiratory-Syndrome Treatment Market?
The increase in respiratory ailments is anticipated to fuel the expansion of the market for severe acute respiratory syndrome treatment. Respiratory disorders, which are medical conditions impacting the respiratory system responsible for breathing and gas exchange between the body and its surroundings, often require severe acute respiratory syndrome treatment for symptoms relief, prevention of respiratory failure, inflammation reduction, and maintenance of oxygen levels. For example, the National Asthma Council, a non-profit organization in Australia dedicated to enhancing asthma care and management, reported in November 2023 that there were 467 deaths due to asthma in 2022, including 299 females and 168 males. This number shows a rise from the 355 deaths recorded in 2021. As a result, the increasing prevalence of respiratory illnesses is promoting the expansion of the severe acute respiratory syndrome treatment market.
What Segmentation Insights Are Provided In The Severe Acute Respiratory-Syndrome Treatment Market Research?
The severe acute respiratory-syndrome treatmentmarket covered in this report is segmented –
1) By Drug Class: Antibiotics; Antiviral; Corticosteroids; Monoclonal Antibodies; Other Drug Classes
2) By Route Of Administration: Oral; Intravenous
3) By Indication: Severe Acute Respiratory Syndrome COVID-19 (SARS-CoV); Severe Acute Respiratory Syndrome COVID-19 2 (SARS-CoV-2)
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
Subsegments:
1) By Antibiotics: Broad-Spectrum Antibiotics; Narrow-Spectrum Antibiotics
2) By Antiviral: Nucleoside Analogs; Protease Inhibitors
3) By Corticosteroids: Systemic Corticosteroids; Inhaled Corticosteroids
4) By Monoclonal Antibodies: Neutralizing Antibodies; Non-Neutralizing Antibodies
5) By Other Drug Classes: Immunomodulators; Supportive Medications
Which Market Trends Are Expected To Define The Future Of The Severe Acute Respiratory-Syndrome Treatment Market?
In order to maintain their foothold in the market for severe acute respiratory syndrome treatment, key players are exploring innovative methods such as multiplexed real-time PCR. Multiplexed real-time PCR is a technology in molecular biology that allows the amplification and identification of numerous DNA or RNA targets in one single procedure. For example, in July 2022, TransGen Biotech Co. Ltd., a Beijing-based entity specializing in molecular and cellular biology products, introduced the Trans-SARS-CoV-2, Influenza A and B and Respiratory Syncytial Virus Assay. This groundbreaking assay is a multiplexed real-time PCR (polymerase chain reaction) assay capable of identifying and differentiating between severe acute respiratory syndrome COVID-19 2 (SARS CoV 2), Influenza A, Influenza B, and the respiratory syncytial virus (RSV) within a single sample. It also serves as an essential tool in diagnosing and treating SARS, influenza, and RSV, offering a way to inform treatment decisions and limit the diseases’ spread.
Who Are The Leading Companies Driving The Severe Acute Respiratory-Syndrome Treatment Market?
Major companies operating in the severe acute respiratory-syndrome treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck And Co Inc., Novartis AG, Bristol Myers Squib company, GlaxoSmithKline PLC, AstraZeneca PLC, Sanofi SA, Eli Lilly And Company, Gilead Sciences Inc., Amgen Inc., Johnson And Johnson Private Limited, Moderna Inc., Regeneron Pharmaceuticals Inc., Hetero labs Ltd., Alexion Pharmaceuticals Inc., Cadila healthcare Ltd., Genentech Inc., Cipla Ltd., Biogen Inc., Vir Biotechnology Inc., Swedish Orphan Biovitrum AB, Dynavax Technologies Corporation, ViiV Healthcare Limited, Panacea Biotec Limited, CureVac N.V., CN Bio Innovations Ltd., Inovio Pharmaceuticals Inc., Chimerix Inc.
Access The Complete Report Here:
Which Geographic Regions Are Creating Strong Demand In The Severe Acute Respiratory-Syndrome Treatment Market?
North America was the largest region in the severe acute respiratory syndrome treatment market in 2024. Western Europe is expected to be the fastest-growing region in the forecast period. The regions covered in severe acute respiratory syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=13027&type=smp
Browse Through More Reports Similar to the Global Severe Acute Respiratory-Syndrome Treatment Market 2025, By The Business Research Company
Respiratory Devices And Equipment Therapeutic And Diagnostic Global Market Report 2025
Respiratory Disposables Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/respiratory-disposables-global-market-report
Respiratory Devices And Equipment Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
